- ImmuPharma said talks with Incanthera to develop the company's Nucant cancer programme were continuing in 'good faith' even as an exclusivity agreement that prevented the company from seeking commercial deals with other parties had expired.

The terms of the definitive licence agreement were expected to include Incanthera paying a licence payment to ImmuPharma of £1m, and foot the bill on all the development costs for the Nucant programme; with future commercialisation revenues shared equally between the two companies.

But Incanthera failed to finalise the terms of a definitive licence agreement before the expiry of the exclusivity period on 31 March 2019.

The exclusivity period had now expired and ImmuPharma was free, should it wish, to discuss collaborations with other parties for the Nucant cancer programme, the company said, but added that discussions with Incanthera were continuing in good faith for a broader collaboration.

There can be no guarantee that any agreement would be reached with Incanthera on a broader collaboration.

At 9:34am: [LON:IMM] ImmuPharma PLC share price was -0.65p at 10.93p

Story provided by